Skip to content

Therapeutic Hypercapnia After Aneurysmal Subarachnoid Hemorrhage - Optimum Duration of Hypercapnia

Therapeutic Hypercapnia After Aneurysmal Subarachnoid Hemorrhage - Study for the Optimum Duration of Hypercapnia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04687605
Enrollment
12
Registered
2020-12-29
Start date
2015-01-31
Completion date
2017-12-31
Last updated
2020-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasospasm Intracranial

Keywords

SAH, Hypercapnia, DCI

Brief summary

Temporary hypercapnia leads to a reproducible increase of cerebral blood flow (CBF) and brain tissue oxygenation (StiO2) as shown in a previous study (Trial-Identification: NCT01799525). The aim of this study now was to measure the course of carbon dioxide partial pressure (pCO2) reactivity after prolonged hypercapnia, and to evaluate the therapeutic effect of graded hypercapnia.

Detailed description

Cerebral vasospasm still is the leading cause of delayed cerebral ischemia (DCI) and secondary ischemic deficits after aneurysmal subarachnoid hemorrhage (SAH). Hypercapnia leads to a reproducible increase of cerebral blood flow (CBF) and brain tissue oxygenation (StiO2) as shown in a previous study (Trial-Identification: NCT01799525). Furthermore, the increase of CBF and StiO2 sustained after normalization of ventilation and no rebound effect was found. So, a possible optimization of the hypercapnic period may lead to prolonged effects of increased CBF and StiO2. Aim of this stuy is to find the ideal duration of hypercapnia and to evaluate the therapeutic effect of graded hypercapnia. For this, intubated and mechanically ventilated patients with an aneurysmal SAH Hunt/Hess 3-5, Fisher grade 2-4 on the initial CT scan and supplied with an external ventricular drainage will be included within the first 96 hours after ictus. Between day 4 and 14 they undergo a trial intervention in which the respiratory minute volume will be reduced in order to maintain a target PaCO2 of 50 - 55 mmHg for 2 hours. Arterial blood gas analysis (ABG) and transcranial Doppler sonography (TCD) is performed in 15-minute intervals. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and cardiovascular parameters are monitored continuously, serial measurement of CBF and StiO2 under continous hypercapnia is performed. Primary endpoint of this trial is change of CBF under hypercapnia, secondary endpoints are StiO2, measures non-invasively with near-infrared spectroscopy, mean flow velocity of intracranial vessels in TCD, delayed cerebral infarction in cranial CT and Glasgow Outcome Score (GOS) after 6 months.

Interventions

PROCEDURETemporary hypercapnia

Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH

Sponsors

University of Wuerzburg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aneurysmal SAH * Aneurysm occluded by clipping/coiling within 96 hours * Hunt/Hess 3-5 * Fisher 2-4 on initial CT scan * Intubated, sedated and mechanically ventilated patient * Continous drainage of cerebrospinal fluid (CSF)

Exclusion criteria

* Age under 18 years * Pregnancy * Common obstructive lung disease (COLD) * potential of hydrogen (pH) in ABG \< 7,25 * ICP \> 20 mmHg

Design outcomes

Primary

MeasureTime frameDescription
Cerebral blood flow (CBF)2-4 hours, day 4-14 after SAHChanges of CBF (absolute, ml/100g tissue/min) under changes of arterial pCO2

Secondary

MeasureTime frameDescription
Cerebral tissue oxygen saturation2-4 hours, day 4-14 after SAHChanges of tissue oxygen saturation measured by near-infrared spectroscopy (NIRS)
Glasgow Outcome Score (GOS)up to 6 monthsGlasgow Outcome Score (GOS 1 - 5, GOS 1 = Death, GOS 5 = none or low disability) after 14 days, after discharge and 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026